{
    "Trade/Device Name(s)": [
        "Dexcom G7 Continuous Glucose Monitoring System",
        "Dexcom G7 CGM System",
        "G7"
    ],
    "Submitter Information": "Dexcom Inc.",
    "510(k) Number": "K240902",
    "Predicate Device Reference 510(k) Number(s)": [
        "K234133"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "KGX"
    ],
    "Summary Letter Date": "April 23, 2024",
    "Summary Letter Received Date": "April 2, 2024",
    "Submission Date": "April 1, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "Wearable sensor"
    ],
    "Instrument(s)/Platform(s)": [
        "Dexcom G7 sensor and transmitter",
        "G7 Mobile Application (iOS/Android smart device)",
        "G7 Receiver"
    ],
    "Method(s)/Technology(ies)": [
        "Wire-type electrochemical sensing",
        "Bluetooth Low Energy wireless communication"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Receiver",
        "Software",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G7 Continuous Glucose Monitoring System for real-time diabetes management in users age 2+.",
    "Indications for Use Summary": "For real-time, continuous glucose monitoring and diabetes management in persons 2 years and older; intended to replace fingerstick testing for diabetes treatment decisions and autonomously communicate with connected devices, including automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}